BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.

Beatriz Felicio Ribeiro,Bruna Vergilio,Eliana Cristina Martins Miranda,Maria Helena Castro de Almeida,Marcia Torresan Delamain,Rosana A Silveira,Carmino Antonio de Souza,Dulcinéia Martins Albuquerque,Andrey Santos,Vagner O Duarte,Gislaine Borba Oliveira-Duarte,Irene Lorand Metze,Katia Borgia Barbosa Pagnano

BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.

2015

Beatriz Felicio Ribeiro
Bruna Vergilio
Eliana Cristina Martins Miranda
Maria Helena Castro de Almeida
Marcia Torresan Delamain
Rosana A Silveira
Carmino Antonio de Souza
Dulcinéia Martins Albuquerque
Andrey Santos
Vagner O Duarte
Gislaine Borba Oliveira-Duarte
Irene Lorand Metze
Katia Borgia Barbosa Pagnano

Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib wh

Keywords:

Tyrosine kinase
Immunology
Medicine
Myeloid leukemia
ABL
Nilotinib
breakpoint cluster region
Imatinib
Dasatinib
second line
single institution
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations